Tuesday, December 6, 2011
Spectrum Pharmaceuticals Inc., of Henderson, Nev., said it filed an investigational new drug application for SPI-014 (formerly called Renazorb), a second-generation lanthanum-based nanoparticle phosphate binding agent that has the potential to treat hyperphosphatemia in patients with Stage V chronic kidney disease, or end-stage renal disease. The company anticipates starting Phase I studies as soon as possible after FDA review.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.